Press Release

The placebo controlled Phase III study assessed the efficacy and safety of once-daily dose-optimised GXR in the treatment of children and adolescents aged 6-17 years with moderate-to-severe symptoms of ADHD. Subjects were randomised to receive GXR 1-4 mg/day (children)/ 4-7 mg/day (adolescents), placebo or atomoxetine (ATX) 10-100 mg/day as a reference arm to validate the study design. 1 As ATX …

from Content Keyword RSS http://ift.tt/1DvosPS http://ift.tt/eA8V8J

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s